The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Addressing individual treatment goals is crucial to patient satisfaction1-3

Human silhouette illustrating the many manifestations of psoriasis: scalp psoriasis, skin plaques, pruritus, nail psoriasis, scalp psoriasis, dactylitis, joint pain, and palmoplantar psoriasis

The numbers*
The impact
Of patients with psoriasis, 62% have scalp symptoms 22% have nail symptoms Though they represent a small portion of BSA, scalp and nail symptoms significantly impact QoL
43% of patients with psoriasis identified pruritus as the most bothersome symptom of their disease Reduction in pruritus is correlated with improvements in QoL
22% of patients with psoriasis and a BSA of ≤3 palms rated their disease as "severe" BSA is not the only factor that contributes to patient perception of disease severity
Up to 35% of patients with psoriasis develop PsA PsA leads to disability and significantly impacts QoL
In more than 80% of patients, psoriasis affects their overall emotional state and interferes with their enjoyment of life The emotional burden of psoriasis remains high, and dissatisfaction with current treatment is prevalent
Patients with moderate psoriasis are more likely to report dissatisfaction with treatment3


Infographic about the unmet needs of people with psoriasis. Only 27% of patients believe that their treatment enables them to lead a normal everyday life. 48% of patients have confidence in their treatment. 77% of patients identified fewer side effects as an important unmet need in treatment. 74% of patients feel that there should be less time devoted to daily treatment. 39% of patients with a BSA of 4 to 10 palms rated their disease as 'severe.' Up to 36% of patients with moderate psoriasis go untreated. Approximately 30% of patients with moderate psoriasis who are receiving treatment are treated with topical therapy alone.

For patients with moderate plaque psoriasis,
traditional systemic therapy may not be enough

aData from the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, a population-based survey of 3,426 patients in North American and Europe.

bBased on the national survey data collected by the National Psoriasis Foundation in the United States. Survey data were collected from randomly sampled patients with psoriasis and psoriatic arthritis in the US population from a database of more than 76,000 patients with psoriatic disease.

*Based on the Multinational Assessment of Psoriasis and Psoriatic Arthritis survey, a survey of 3,426 patients with psoriasis and psoriatic arthritis, the WHO 2016 Global Report on Psoriasis and the National Psoriasis Foundation Survey (2003-2011), a survey of 5,604 psoriasis and psoriatic patients in the US.

Cross-sectional study of patients undergoing treatment for dermatological diagnoses (N = 500), including psoriasis vulgaris. Results are based on responses to the Patient Benefit Questionnaire and include only those patients with psoriasis (n = 50). Percentages reflect patients indicating moderate or high benefit on a scale from 0 (not at all) to 4 (strongly).

BSA, body surface area; QoL, quality of life.


  1. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.
  2. WHO Psoriasis Report 2016.
  3. Armstrong A, Robertson A, Julie W, et al. Undertreatment, treatment needs, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States. JAMA Dermatol. 2013;149(10):1180-1185.
  4. Augustin M, Radtke M, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301(8):561-571.
  5. Iversen L, Paul C, Cirulli J, et al. Efficacy of apremilast vs placebo in patients with lower plaque psoriasis disease activity: results of a pooled, post-hoc analysis of the ESTEEM 1 and 2 trials. Poster presented at: the 26th Congress of the European Academy of Dermatology and Venereology; 13-17 September 2017; Geneva, Switzerland.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.